Inventiva S.A. Form 6-K Summary
Business context and reporting period
Inventiva S.A., a French biopharmaceutical company headquartered in Daix, France, furnished this Form 6-K for June 2024. The report was signed and filed on June 5, 2024, and relates primarily to the company’s upcoming shareholder meeting.
Key financial metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
Material developments
- On June 3, 2024, Inventiva published a notice for its Ordinary and Extraordinary General Meeting.
- The meeting is scheduled for June 20, 2024, at 9:00 a.m. at Hôtel Castel Burgond in Daix, France.
- The notice is furnished as Exhibit 99.1.
Guidance, outlook, risks, and unusual items
The filing does not provide financial guidance, operating outlook, management commentary, new risk disclosures, contingencies, or unusual financial items. The report states that the information, including Exhibit 99.1, is furnished rather than filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Important facts for investors to verify
- Review the complete notice of meeting and the proposed resolutions in Exhibit 99.1.
- Confirm the outcomes of the June 20, 2024 Ordinary and Extraordinary General Meeting.
- Consult Inventiva’s periodic reports for current financial condition, liquidity, financing needs, clinical-program developments, and risk factors, none of which are addressed in this Form 6-K.